Liso-cel for newly treated primary CNS lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have primary CNS lymphoma (a lymphoma that started in your brain or spinal cord), confirmed by a biopsy.
- You must not be eligible for a stem cell transplant due to age (65 or older) or other health issues (HCT-CI score of 3 or higher).
- You must have received 4 to 6 rounds of high-dose methotrexate as your only chemotherapy, and your tumor must have shrunk or disappeared after that treatment.
- You must be in generally good health (able to care for yourself), with no active hepatitis B or C, HIV, or other cancers in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests a combination of two drugs for people with large B-cell lymphoma that has spread to the brain or spinal cord and has come back or not responded well to earlier treatments. The first drug, Relma-cel, is a type of immunotherapy that helps your immune system attack cancer cells. The second drug, Tislelizumab, helps keep your immune system active against the cancer.
This trial tests a new treatment combining CAR-T cell therapy with stem cell transplant and two targeted drugs for patients with a type of brain lymphoma called PCNSL that has come back or not responded to first-line treatment.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.